Gilead wins reversal of $2.54 bln hepatitis C drug patent verdict
February 17, 2018 at 09:41 AM EST
Feb 17 (Reuters) - A federal judge in Delaware has overturned a jury's verdict requiring Gilead Sciences Inc to pay a record $2.54 billion because its hepatitis C drugs Sovaldi and Harvoni infringed a patent held by rival Merck & Co Inc.